Présentation et pronostic des adénomes thyréotropes : à propos de trois observations

Latrech, H.; Rousseau, Audrey; Marois, Edith; Billaud, L; Bertagna, Xavier; Azzoug, S.; Raffin-Sanson, Marie-Laure

doi:10.1016/j.revmed.2010.09.018

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Somatostatin analogs are administered after transsphenoidal surgery for long-term control of residual disease [2]. For example, in a series of 73 patients treated with octreotide (50 to 750 micrograms subcutaneously two or three times a day), most of whom had already undergone surgery, the following results were observed: TSH serum concentration decreased by over 50 percent in 92 percent of patients and normalized in 79 percent; Serum concentrations of T4 and T3 returned to normal in 95 percent of patients after one year; The tumor size decreased in 52 percent of patients after one year; Less than 10 percent of patients developed resistance to the action of octreotide.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

TSH-Secreting Pituitary Tumors: A Case Series and Literature Review

Gaytan Liliana,

Marco Antonio,

Soto Adriana

et al. 2024

J Sur Anesth Res

View full text Add to dashboard Cite

Objectives: To present a series of 3 patients with TSHomas and a brief literature review. Background: TSH-secreting pituitary neuroendocrine tumors (PitNETs) account for <1% of all adenomas observed in surgical series. Most are macroadenomas, and diagnosis can be delayed by up to 9.5 years. Early diagnosis and appropriate treatment can prevent the occurrence of neurological and endocrinological complications. Surgical resection is the first-line treatment. A literature review will be presented to summarize current evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Thyrotropinomas are observed in patients ranging from 8 to 84 years of age, primarily in the fifth and sixth decades of life. The prevalence of tumors does not seem to differ between men and women [1,2].…”

Section: Introductionmentioning

confidence: 86%

TSH-Secreting Pituitary Tumors: A Case Series and Literature Review

Gaytan Liliana,

Marco Antonio,

Soto Adriana

et al. 2024

J Sur Anesth Res

View full text Add to dashboard Cite

show abstract

The outcome of TSHoma from a tertiary care institute in India

Dutta

Jain

Rai

et al. 2021

Surgical Neurology International

View full text Add to dashboard Cite

Background: Thyroid-stimulating hormone (TSH)-secreting pituitary adenoma (TSHoma) is the rarest functioning pituitary adenoma. Methods: A retrospective analysis of eight patients of TSHomas to highlight the presentations, diagnostic challenges, and treatment outcomes. Results: Median age at diagnosis was 42 years, median latency to diagnosis was 2.5 years, and thyrotoxic and compressive symptoms were the most common presenting symptoms. At presentation, three cases were plurihormonal, six cases were on medical treatment including thyroxine, and two cases were incidentally discovered. Imaging revealed macroadenoma in all cases. Seven cases underwent pituitary surgery, after which three achieved remission. Another case entered remission after adjunctive radiotherapy. Thyrotropin (TSH) immunostaining was demonstrated in six out of seven adenomas. Conclusion: TSHoma is a rare functioning pituitary tumor with both silent and symptomatic presentations. Diagnosis can be established with biochemical and imaging features, even without dynamic tests.

show abstract